Azargen was founded in 2006 by Mauritz Venter and Cobus Zwiegelaar, who still run the business today. They have raised over R 50 million rand, with the largest investment coming from shareholder IDC (Industrial Development Corporation). In addition to securing numerous international patents, they are one of a few South African biotechs to be granted a pre IND with the US FDA, to provide guidance for manufacturing, pre-clinical and clinical development of plant made rituximab.
Menu
